Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $15.7143.

Several equities analysts have issued reports on ALT shares. William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th. Wall Street Zen cut Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright restated a “buy” rating and issued a $20.00 price target (down from $25.00) on shares of Altimmune in a report on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Friday, March 27th. Finally, Citigroup restated a “market outperform” rating on shares of Altimmune in a report on Tuesday, June 2nd.

Altimmune Stock Performance

NASDAQ ALT opened at $2.93 on Tuesday. The company has a current ratio of 29.56, a quick ratio of 29.56 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $2.95 and its two-hundred day moving average is $3.80. Altimmune has a 12-month low of $2.56 and a 12-month high of $7.73. The stock has a market capitalization of $569.80 million, a price-to-earnings ratio of -3.15 and a beta of 0.21.

Altimmune (NASDAQ:ALT) last released its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. Research analysts expect that Altimmune will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Altimmune

A number of institutional investors and hedge funds have recently modified their holdings of ALT. Arax Advisory Partners grew its holdings in shares of Altimmune by 99.7% in the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock worth $29,000 after acquiring an additional 4,076 shares during the period. SBI Securities Co. Ltd. grew its holdings in shares of Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares during the period. Quantinno Capital Management LP acquired a new stake in shares of Altimmune in the 1st quarter worth approximately $33,000. Quadrature Capital Ltd acquired a new stake in shares of Altimmune in the 4th quarter worth approximately $36,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Altimmune in the 3rd quarter worth approximately $38,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.